The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1668
January 23, 2023
View Complete Issue         Table of Contents 2019 
Hemgenix - A Gene Therapy for Hemophilia B
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Hemgenix - A Gene Therapy for Hemophilia B
January 23, 2023 (Issue: 1668)
Etranacogene dezaparvovec-drlb (Hemgenix – CSL Behring), an adeno-associated virus vector-based gene therapy, has been approved by the FDA for treatment of hemophilia B in adults who currently receive factor IX prophylaxis therapy or have...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Hemgenix - A Gene Therapy for Hemophilia B
Article code: 1668a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.